DEXCOM INC 8-K

What Happened
Dexcom, Inc. announced on February 26, 2026 (Form 8-K) that its Board increased in size to twelve directors and appointed Albert F. (“Rick”) Osterloh IV as a director, effective immediately. Mr. Osterloh was named to the Board’s Compensation Committee and Technology Committee and will serve until the 2026 annual meeting of stockholders.

Key Details

• Appointment effective: February 26, 2026; Board size increased to 12 directors.
• Term: Mr. Osterloh’s term expires at Dexcom’s 2026 annual stockholders meeting.
• Committee roles: Member of the Compensation Committee and the Technology Committee.
• Compensation: Initial appointment granted RSUs with a fair value of $500,000 vesting annually over three years; eligible for a pro‑rated 2026 annual RSU award valued at $101,027 (pro‑rated from a $325,000 base). Vesting of non-employee director awards accelerates in full upon a change in control.
• Governance: Board determined Mr. Osterloh qualifies as an independent director; he entered Dexcom’s standard director indemnity agreement.
• Disclosure: Appointment announced via press release furnished as Exhibit 99.1 in the 8-K.

Why It Matters
A new independent director can affect governance and oversight—especially given Mr. Osterloh’s placement on the Compensation and Technology Committees, which oversee pay programs and technology strategy. The RSU awards are standard non-employee director compensation but represent potential future dilution if shares are issued upon vesting. Investors should note the board expansion and committee changes as part of ongoing governance developments; there were no disclosed related-party transactions or other material terms beyond standard indemnity and compensation arrangements.